Eye­ing a po­ten­tial mar­ket launch, Astel­las or­ders up a $95M third course of Cy­to­ki­net­ics’ pipeline

What­ev­er Astel­las learned about Cy­to­ki­net­ics $CYTK in the three years since first sign­ing on as a col­lab­o­ra­tor, the ex­pe­ri­ence must have giv­en its re­search team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.